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ABSTRACT 
Aim: In addition to TNM stage, there are adverse tumour and host factors, such as venous 
invasion and the presence of an elevated systemic inflammatory response (SIR) that influence 
the outcome in colorectal cancer. The present study aimed to examine how these factors varied 
in screen detected (SD) and non-screen detected tumours (NSD).  
Method: Prospectively maintained databases of  the prevalence round of a biennial population 
FOBt screening programme and a regional cancer audit database were analysed. Interval 
cancers (INT) were defined as cancers identified within two years of a negative screening test. 
Results: Of the 395 097 invited, 204 535 (52%) responded, 6159 (3%) tested positive, and 421 
(9%) had cancer detected. From this cohort, a further 708 (63%) NSD patients were identified 
(468 (65%) non-responders, 182 (25%) INT cancers and 58 (10%) did not attend or did not 
have cancer diagnosed at colonoscopy). Comparing SD and NSD patients, SD patients were more 
likely to be male, and have a tumour with a lower Dukes stage (both p<0.05). On stage-by-stage 
analysis, SD patients had less evidence of an elevated SIR (p<0.05). Both the presence of venous 
invasion (p=0.761) and an elevated SIR (p=0.059) were similar between those with INT cancers 
and in those that arose in non-responders. 
Conclusion: Independent of TNM stage, SD tumours have more favourable host prognostic 
factors than NSD tumours. There is no evidence that INT cancers are biologically more 
aggressive than those that develop in the rest of the population and hence are likely to be due to 
limitations of screening in its current format.  
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 INTRODUCTION 
The outcome following a diagnosis of colorectal cancer is directly related to the stage at 
diagnosis, with over 90% of those who undergo resection for Stage 1 disease alive at 5-years 
compared with less than 50% for Stage III disease [1]. Independent of the TNM stage, 
however,there are other additional adverse features of the tumour itself and the patient, the so 
called ‘host’, that have been shown to predict a worse outcome. For example, the presence of 
venous invasion or poor differentiation, are now used in clinical practice to help identify 
patients with more aggressive Stage II disease who are at a higher risk and hence may benefit 
from adjuvant chemotherapy [2-4]. It has been argued recently that the combination of T-stage 
and venous invasion is superior to the traditional TNM stage in predicting outcome in node 
negative disease [5]. 
There is now a wealth of evidence that the presence of an elevated host systemic inflammatory 
response (SIR) is an independent negative prognostic factor in patients with cancer [6]. The SIR 
can be assessed routinely with standard bedside tests such as C-reactive protein (CRP) or the 
neutrophil to lymphocyte ratio (NLR) [7-11]. In the case of colorectal cancer specifically, those 
with an elevated pre-operative SIR have a poorer outcome independent of the TNM stage [7,12]. 
 
 
What does this paper add to the literature? 
In addition to having tumours of an earlier stage, patients with tumours detected through the 
FOBt screening programme have improved host prognostic factors, in terms of a lower pre-
operative systemic inflammation response, than patients with non screen-detected disease.  
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Screening for colorectal cancer using the guaiac-based faecal occult blood test (gFOBt) increases 
the number of early stage cancers diagnosed and reduces cancer specific mortality [13-15]. In 
addition, there is increasing evidence that screening using the faecal immunochemical test (FIT) 
may have improved sensitivity over gFOBt [16-18]. This has lead to the development of the 
Scottish Bowel Screening Programme (SBoSP), which is a combined gFOBt/FIT population 
based screening programme [19]. This has been found to detect a large number of early stage 
tumours, although interval cancers (tumours that develop within two years of a negative 
screening test) do develop [20].  
In assessing the efficacy of colorectal cancer screening, previous work has examined differences 
between screen-detected and non screen-detected disease and has shown improved survival in 
screen-detected patients [21-27]. Such analysis has, however, focused on the stage and site of 
tumours and only one such study has included detailed analysis of adverse tumour factors 
beyond TNM stage that are of independent prognostic significance [21]. Furthermore, to date, 
no previous studies have included assessment of the pre-operative host systemic inflammatory 
response within the context of a colorectal cancer screening programme. The aim of the present 
study was to examine the efficacy of the first round of a population based gFOBt/FIT colorectal 
cancer screening programme in our geographical area with regard to cancer detection rates, 
and to compare and contrast adverse tumour and host prognostic factors in screen-detected 
and non screen-detected colorectal cancer.  
METHOD 
Details of all individuals who were invited to the first round of the SBoSP during April 2009 to 
the end of March 2011 in NHS Greater Glasgow & Clyde (NHS GG&C) were extracted from the 
prospectively maintained NHS GG&C Bowel Screening IT System (original date of extraction 
January 2012, updated April 2014). They included all individuals, in NHS GGG&C, aged between 
50 and 74 years, who were registered with a General Practitioner. Methodology data on the 
screening algorithm and processing of samples of the SBoSP have been described previously 
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[19]. Briefly, individuals are sent a pre-invitation letter and then a gFOBt kit (hemascreen, 
Immunostics, Ocean, New Jersey, USA, supplied by Alpha Laboratories, Eastleigh, Hampshire, 
UK) and referred for colonoscopy if this is returned and is strongly positive (>5 of 6 windows 
positive).  In the case of a weakly positive gFOBt (1-4 of 6 windows positive) or spoiled or 
untestable kit a confirmatory FIT kit (hema-screen SPECIFIC, Immunostics, Ocean, New Jersey, 
USA, supplied by Alpha Laboratories, Eastleigh, Hampshire, UK) is sent. Data were extracted on 
individuals invited for screening,including the  combined gFOBt/FIT result and the uptake and 
result of colonoscopy. 
All individuals invited for screening in this first round were cross-referenced with the 
prospectively maintained West of Scotland Colorectal Cancer Managed Clinical Network (MCN) 
dataset and also linked to the Scottish Cancer Registry (SMR06).  This allowed the identification 
of any patient with a diagnosis of colorectal cancer. As screening invitations were biennial, 
patients with cancer detected more than 720 days after screening invite were excluded. Patients 
with colorectal cancer were then categorised as having screen-detected disease (SD), or non 
screen-detected disease (NSD). NSD patients were then further characterised as non-
responders to the screening invitation (NR), having an interval cancer detected following a 
negative gFOBt/FIT (INT), having a cancer in a patient who tested positive but did not attend 
for colonoscopy (NA) or having a cancer in a patient who did not have cancer detected at 
colonoscopy following a positive screening test (CN). Patients who had an initially suspicious 
adenoma detected through screening and as a result of subsequent investigations had colorectal 
cancer detected within six months of the invitation for screening were termed SD.  
Individual patient records were then interrogated on a case-by-case basis to identify further 
clinicopathological variables for analysis. Tumours were staged according to the conventional 
tumour node metastasis (TNM) classification (5th Edition) [28]. Polyp cancers that were 
managed endoscopically, and did not undergo formal resection were assumed to be node 
negative and classified as TNM Stage I. Additional high-risk tumour features, such as poor 
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differentiation, the presence of venous invasion, peritoneal involvement and margin 
involvement, were identified from pathology reports.  
Both the absolute neutrophil count and the neutrophil to lymphocyte ratio (NLR) were used as 
markers of the pre-operative SIR and were obtained from pre-operative blood results taken 
most immediately and not more than six weeks before surgery.  A previously validated 
threshold of an NLR of >5 was used as evidence of a significantly elevated SIR [9]. An absolute 
neutrophil level greater than 7.5 x 109 /litre was defined as elevated based on local laboratory 
guidelines.  
Permission for the study was granted by the Caldicott Guardian of the Screening dataset and by 
the West of Scotland Colorectal Cancer MCN Management group. Data were stored and analysed 
in an anonymised manner. 
 
Statistical analysis 
Associations between categorical variables were examined using the χ2 test.  For ordered 
variables with multiple categories the χ2 test for a linear trend was used. Fisher’s exact test was 
used for assessing associations where the expected individual cell counts were less than 5. A 
value of p<0.05 was considered statistically significant. Statistical analysis was performed using 
SPSS software (SPSS Inc., Chicago, IL, USA) 
 
RESULTS 
From April 2009 to March 2011, representing the first complete round of screening in NHS 
GG&C, 395 097 individuals were invited to participate, 204 535 (52%) responded and 6 159 
(3.0%) tested positive. Of those who tested positive, 4 797 (78%) individuals proceeded to 
colonoscopy and 421 patients had cancer detected (SD) (Figure 1). These figures differ slightly 
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from previously published work by our group due to updating of the data within the Bowel 
Screening IT System [29]. After cross-referencing with MCN and SMR06 datasets, 708 patients 
with NSD colorectal cancer were identified (468 (65%) patients NR; 182 (25%) patients INT, 43 
(6%) patients NA; 15 (2%) patients CN). This generated an estimated sensitivity and specificity 
of the first round of the gFOBt/FIT screening test, for the detection of cancer of 72.4% and 
97.2% (Supplementary Table 1). 
 
Comparison of Screen-detected and Non Screen-detected Colorectal cancer 
SD patients were more likely than NSD patients to be male (p=0.002), have more distal disease 
(p=0.003), which was of an earlier stage (p<0.001) and were more likely to undergo a 
procedure with a curative intent (p<0.001) (Table 1). In those undergoing a curative procedure, 
SD patients had a less advanced T-stage and less evidence of venous invasion, peritoneal 
involvement and margin involvement (p<0.05). They also had less evidence of an elevated pre-
operative SIR judged by the NLR and the absolute neutrophil count (Table 2). A stage by stage 
analysis of factors was then carried out (Supplementary Table 2). Patients with SD tumours had 
less evidence of an elevated SIR in stage II and III disease. There was no significant difference in 
venous invasion rates between SD and NSD tumours in all four stages (Supplementary Table 2).  
Comparison of Interval and Screen-detected Cancers 
INT patients were more likely than SD patients to be female (p<0.001), have more proximal 
disease (p<0.001), have more advanced disease (p<0.001) and less likely to be managed with a 
curative intent (p<0.001) (Table 3). In addition, they were more likely to have adverse 
prognostic factors such as venous invasion (p=0.026) and an elevated pre-operative SIR 
(p=0.025) (Table 3). On stage by stage analysis, however, these differences failed to retain 
statistical significance. In particular, venous invasion rates were similar in Stage 1 (17% INT vs 
25% SD, p=0.344), Stage II (57% INT vs 47% SD, p=0.272) and Stage III (71% INT vs 70% SD, 
p=0.970) disease.   
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Comparison of Interval and Non-Responder Cancers 
INT patients were more likely than NR patients to be female (p=0.034) (Table 4). There was 
trend towards INT patients having less advanced (p=0.052) and more proximal disease 
(p=0.090) but this did not reach significance at the 5% level. When patients who were treated 
with a curative intent were examined, there was no difference in adverse pathological features 
between INT and NR patients. There was a trend for NR patients have an elevated preoperative 
SIR (p=0.059) compared with INT patients (Table 4). 
 
DISCUSSION 
The results of the present study provide a comprehensive analysis of the outcome from the first 
round of a stool-based colorectal cancer screening programme. It confirms previous studies that 
have found that screen-detected tumours are of an earlier stage than non screen-detected 
tumours and reports for the first time that individuals with screen-detected disease have more 
favourable host prognostic factors than those with non screen-detected disease.    
Analysis of host factors, such as the presence of an elevated SIR has not previously been 
examined within the context of a colorectal cancer screening programme. In addition to 
inflammatory responses in the tumour micro-environment [30], systemic inflammatory 
responses are now recognised as a key hallmark of cancer [6]. In particular there is a wealth of 
evidence that host factors are associated with an adverse outcome in colorectal cancer including 
meta-analyses [7,11]. To date, however, their inclusion as a means of predicting outcome 
outside in the routine clinical setting has been patchy. In the present study the most readily 
available measure of the systemic inflammatory response, in the form of neutrophils and the 
neutrophil to lymphocyte ratio has been included [31,32]. This additional information adds to 
the level of detail available for the cohort and is a unique feature of this comprehensive analysis. 
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It could be argued that the present study, showing that some adverse tumour prognostic factors 
are less prevalent in SD tumours than in NSD tumours, is evidence for the effect of length-time 
bias where the identification of indolent slow growing tumours artificially improves cancer-
specific survival by detecting those who have a longer pre-clinical phase [33]. When, however, 
adjustment is made for stage, the two key features in keeping with phenotypically more 
aggressive tumours, venous invasion and poor differentiation, do not achieve statistical 
significance. Furthermore, it has previously been postulated that INT tumours not only 
represent tumours missed by the screening test itself but may be more aggressive if they 
develop within the screening interval [20]. Examining in detail tumour and host prognostic 
factors in INT compared with NR tumours provides evidence to refute this hypothesis. There 
was no evidence of adverse tumour features in the INT group when compared with the NR 
group in the present study. Indeed, there was a trend for NR patients to have evidence of a 
higher host SIR. Therefore, the conclusion that can be drawn from the present study is that the 
inherent biological characteristics of SD tumours do not differ from those of NSD disease.  
There were higher numbers of cancers in both the NA and CN groups than initially expected. On 
further investigation, however, it became apparent that a substantial proportion of the NA 
patients (40%, data not presented), were already under investigation for colorectal symptoms 
and had sent back the screening test in the midst of undergoing non-screening investigations. 
Also, of the 15 patients who were CN, 12 (80%) (data not presented) had polyps detected at 
colonoscopy and hence were undergoing follow-up. For the purposes of the present study, a 
cancer diagnosis outwith six months of initial colonoscopy was defined as NSD, but it may be 
argued that these patients would not have been detected at that time had they not participated 
in screening. Nevertheless, the 15 patients who were CN represent a post-colonoscopy 
colorectal cancer rate of 3% which compares favourably with  other studies that have examined 
this outwith screening programmes which have provided rates of 2- 8%, albeit with longer (3 to 
5 year) follow-up [34-36]. The majority of post-colonoscopy colorectal cancers are thought to 
arise through procedural factors such as missed lesions and inadequate examination [35]. The 
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SBoSP has tight quality control on all colonoscopists requiring to be Joint Advisory Group (JAG) 
accredited and have a greater than 90% caecal intubation rate [37]. It was not in the scope of 
the present study to examine colonoscopy quality indexes in more detail, but the low rate of 
post-colonoscopy colorectal cancer was reassuring.   
 
Strengths and weaknesses 
The main strengths of the present study include the comprehensive and detailed dataset. Case 
notes were examined on a case-by-case basis allowing for more detailed analysis of 
clinicopathological factors at a depth that has not previously been undertaken. For example, in 
the present study after case note review, only 2% of tumours remained unstaged compared 
with 25% in a previous study using population databases [23]. In addition, we have included 
data from non-responders, which have been absent from other studies, and by utilising regional 
and national cancer registry datasets we have comprehensively captured those with NSD 
disease from corroborative sources. 
The main limitation of the study is the fact that this is a prevalence round of a screening 
programme and as such these results may not be applicable in subsequent rounds. This is 
important when analysing data presented regarding sensitivity and specificity. A further 
possible limitation was that all NSD tumours were taken as the main comparison group. 
Comparing INT to SD tumours might have been a better measure of the impact of screen 
detection.  Nevertheless the present study represents a population setting whereby compliance 
to the screening programme was just over 50%. Therefore to exclude NR tumours, would be to 
exclude from the study a large proportion of the population invited for screening. A subanalysis 
comparing SD with INT tumours was undertaken and no difference in prognostic factors was 
elicited when adjusted for stage. Such subanalyses will by definition be limited by reduced 
numbers and hence power and additional work is required to examine these findings further. 
Finally, our measure of the SIR was by NLR and not the modified Glasgow Prognostic Score 
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(mGPS), which has been shown to be a more sensitive measure of host inflammation with 
regard outcome [8] , but this is a retrospective study, and C-reactive protein required for 
calculating mGPS, was not routinely measured pre-operatively in all hospitals during this 
timeframe.  
 
In conclusion, the present study reports that patients with SD tumours, independent of stage, 
had more favourable host prognostic factors than patients with NSD tumours. There was, 
however, no difference in adverse tumour features associated with an aggressive tumour 
phenotype. In addition, INT cancers did not appear to have more aggressive features than 
tumours that developed in the rest of the population and hence were more likely to arise as a 
result of the limitations of the testing algorithm itself rather than represent biologically more 
aggressive tumours. Further work, identifying a more sensitive test is required to increase the 
number of tumours that are detected through screening and hence to improve the outcome in 
colorectal cancer. 
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Table 1: Baseline characteristics of Screen-detected and Non Screen-detected colorectal 
cancer (all patients) 
 
 
 All 
patients 
n(%) 
 Screen-
detected  
n(%) 
Non Screen-
detected 
n(%) 
 
 
p-
value 
 1129  421 708  
Age      
         <64 437 (39)  164 (39) 273 (39)  
         64 – 70 300 (27)  114 (27) 186 (26)  
         >70 392 (35)  143 (34) 249 (35) 0.762 
Sex      
        Female 447 (40)  142 (34) 305 (43)  
        Male 682 (60)  279 (66) 403 (57) 0.002 
Site      
         Proximal to splenic 
flexure 
325 (29)  100 (24) 225 (32)  
         Distal to splenic flexure  795 (71)  321 (76) 474 (67) 0.003 
         Synchronous 9 (1)  0 9 (1)  
TNM Stage      
         I 318 (28)  191 (45) 127 (18)  
         II 285 (25)  93 (22) 192 (27)  
         III 284 (25)  103 (25) 181 (26)  
         IV 220 (20)  28 (7) 192 (27) <0.001 
         Unstaged 22 (2)  6 (1) 16 (2)  
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Management intent      
         Curative procedure 872 (77)  393 (93) 479 (68)  
         Palliative procedure 102 (9)  8 (2) 94 (13)  
         No procedure 155 (14)  20 (5) 135 (19) <0.001 
 
 
Table 2: Comparison of tumour and host prognostic factors between Screen-detected and Non 
Screen-detected colorectal cancer (patients undergoing a procedure with a curative intent) 
 
 All 
patients 
n(%) 
 Screen-
detected  
n(%) 
Non 
Screen-
detected 
n(%) 
 
 
p-value 
 872  393 479  
T-stage      
         0/1 233 (27)  149 (38) 84 (18)  
         2 124 (14)  63 (16) 61 (13)  
         3 365 (42)  153 (39) 212 (44)  
         4 150 (17)  28 (7) 122 (26) <0.001 
N-stage1      
         0 522 (66)  228 (69) 294 (64)  
         1 182 (23)  73 (22) 109 (24)  
         2 89 (11)  32 (10) 57 (12) 0.138 
Differentiation2               
          Poor 69 (8)  24 (6) 45 (10)  
          Moderate/well 795 (92)  368 (94) 427 (90) 0.066 
Venous Invasion3      
          Present 405 (50)  163 (44) 242 (55)  
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          Absent 413 (50)  213 (57) 200 (45) 0.001 
Peritoneal involvement1      
          Present 128 (16)  20 (6) 108 (24)  
          Absent 665 (84)  313 (94) 352 (77) <0.001 
Tumour Perforation1      
           Present 39 (5)  4 (1) 35 (8)  
           Absent 754 (95)  329 (98) 425 (92) <0.001 
Margin Involvement1      
            Present 27 (3)  5 (2) 22 (5)  
            Absent 766 (97)  328 (98) 438 (95) 0.012 
Absolute neutrophil count4      
            >7.5 x 109 70 (9)  13 (4) 57 (13)  
            <7.5 x 109 710 (91)  315 (96) 395 (87) <0.001 
Neutrophil/lymphocyte ratio4      
            > 5 123 (16)  28 (9) 95 (21)  
            < 5 657 (84)  300 (91) 357 (79) <0.001 
(1. n=793 resections, 2. n= 866 3. n= 818. 4. n=780) 
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Table 3. Comparison of baseline characteristics (all patients) and tumour and host factors 
(patients managed with a curative intent) in patients with Interval and Screen-detected cancers 
 
 Interval  
 
n(%) 
Screen-
detected  
n(%) 
 
p-value 
 
 182 421  
Age    
         <64 64 (35) 164 (39)  
         64 – 70 59 (32) 114 (27)  
         >70 59 (32) 143 (34) 0.765 
Sex    
        Female 91 (50) 142 (34)  
        Male 91 (50) 279 (66) <0.001 
Site    
         Proximal to splenic flexure 69 (38) 100 (24)  
         Distal to splenic flexure  113 (62) 321 (76) <0.001 
         Synchronous 0 0  
TNM Stage    
         I 37 (20) 191 (45)  
         II 45 (25) 93 (22)  
         III 53 (29) 103 (25)  
         IV 46 (25) 28 (7) <0.001 
         Unstaged 1 (1) 6 (1)  
Management intent    
         Curative procedure 130 (71) 393 (93)  
         Palliative procedure 20 (11) 8 (2)  
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         No procedure 32 (18) 20 (5) <0.001 
T-stage1    
         0/1/2 43 (33) 212 (54)  
         3/4 87 (67) 181 (46) <0.001 
N-stage2    
         0 77 (61) 228 (69)  
          1/2 49 (39) 105 (32) 0.137 
Differentiation3            
          Poor 13 (10) 24 (6)  
          Moderate/well 114 (90) 368 (94) 0.118 
Venous Invasion4    
          Present 68 (55) 163 (43)  
          Absent 56 (45) 213 (57) 0.026 
Absolute neutrophil count5    
            >7.5 x 109 12 (9) 13 (4)  
            <7.5 x 109 115 (91) 315 (96) 0.021 
Neutrophil/lymphocyte ratio5    
            > 5 20 (16) 28 (9)  
            < 5 107 (84) 300 (91) 0.025 
 
(1. n= 523(100%) patients managed with a curative intent, 2. n=459 resections, 3. 
n=519(99%) patients managed with a curative intent, 4. n=500 (96%) patients managed 
with a curative intent, 5. n=455 (87%) patients managed with a curative intent) 
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Table 4. Comparison of baseline characteristics (all patients) and tumour and host factors 
(patients managed with a curative intent) in patients with Interval and Non-responder cancers 
 
 Interval  
 
n(%) 
Non-
responder 
n(%) 
 
p-value 
 
 182 468  
Age    
         <64 64 (35) 188 (40)  
         64 – 70 59 (32) 113 (24)  
         >70 59 (32) 167 (36) 0.816 
Sex    
        Female 91 (50) 191 (41)  
        Male 91 (50) 277 (59) 0.034 
Site    
         Proximal to splenic flexure 69 (38) 142 (30)  
         Distal to splenic flexure  113 (62) 317 (68) 0.090 
         Synchronous 0 9 (2)  
TNM Stage    
         I 37 (20) 74 (16)  
         II 45 (25) 130 (28)  
         III 53 (29) 115 (25)  
         IV 46 (25) 135 (29) 0.052 
         Unstaged 1 (1) 14 (3)  
Management intent    
         Curative procedure 130 (71) 306 (65)  
         Palliative procedure 20 (11) 67 (14)  
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         No procedure 32 (18) 95 (20) 0.210 
T-stage1    
         0/1/2 43 (33) 83 (27)  
         3/4 87 (67) 223 (73) 0.210 
N-stage2    
         0 77 (61) 187 (64)  
          1/2 49 (39) 105 (36) 0.569 
Differentiation3            
          Poor 13 (10) 29 (10)  
          Moderate/well 114 (90) 273 (90) 0.840 
Venous Invasion4    
          Present 68 (55) 157 (56)  
          Absent 56 (45) 121 (44) 0.761 
Absolute neutrophil count5    
            >7.5 x 109 12 (9) 41 (15)  
            <7.5 x 109 115 (91) 242 (85) 0.160 
Neutrophil/lymphocyte ratio5    
            > 5 20 (16) 68 (24)  
            < 5 107 (84) 215 (76) 0.059 
 
(1. n= 436(100%) patients managed with a curative intent, 2. n=418 resections, 3. 
n=429(98%) patients managed with a curative intent, 4. n=402(92%) patients managed 
with a curative intent, 5. n=410(94%) patients managed with a curative intent) 
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Figure 1 
 
 
